Spexis to host business update conference call on October 9, 2023
|
Spexis AG
/ Key word(s): Statement
Spexis to host business update conference call on October 9, 2023
Allschwil, Switzerland, October 6, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT. Jeffrey D. Wager, M.D. (CEO Chairman) will provide strategic business and financial updates. To access the conference call please use the following details: France: +33 0805102207 International Toll Free +1 412-317-6789
Event Title: Spexis AG – Business Update Conference Call The conference call will also be available via webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=6s6eCE7g After the call, a replay of the webcast will be available via the above link.
About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com.
For further information please contact: For Investors: Or Stephen Jasper
For Media:
End of Media Release |
| Language: | English |
| Company: | Spexis AG |
| Hegenheimermattweg 125 | |
| 4123 Allschwil | |
| Switzerland | |
| Phone: | +41 61 567 1600 |
| Fax: | +41 61 567 1601 |
| E-mail: | [email protected] |
| Internet: | www.spexisbio.com |
| ISIN: | CH0106213793 |
| Valor: | SPEX |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1742821 |
| End of News | EQS News Service |
|
|
1742821 06.10.2023 CET/CEST
